Showing results (91-100 of 109) with videos related to
Sort By:
Pageof 11
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 11, 2023
Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung CancerRohit Thummalapalli, Biagio Ricciuti, Chaitanya Bandlamudi, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2025
First-line MET tyrosine kinase inhibitors versus immunotherapy ± chemotherapy for patients with MET exon 14 skipping mutant metastatic NSCLCFederica Pecci, Hui Li, Alessandro Di Federico, et al.JTO Clinical and Research Reports|October 14, 2024
Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%-89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With First-Line Pembrolizumab or CemiplimabBiagio Ricciuti, Arielle Elkrief, Jessica Lin, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 27, 2025
Distinct Clinicogenomic Features and Immunotherapy Associations in Pulmonary Sarcomatoid Carcinoma: A Multicenter Retrospective StudyLingzhi Hong, Alessandro Di Federico, Bolun Liu, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2023
Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non-Small Cell Lung CancerBiagio Ricciuti, Arielle Elkrief, Joao Alessi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 11, 2024
Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung CancerBiagio Ricciuti, Giuseppe Lamberti, Sreekar R Puchala, et al.Clinical Lung Cancer|February 28, 2025
Tumor Immunophenotypic Correlates in Patients Aged 80 Years or Older With Non-Small Cell Lung Cancer and Outcomes to First-Line Pembrolizumab in PD-L1 High (≥50%) PatientsAdriana P C Barrichello, Arielle Elkrief, Biagio Ricciuti, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2026
Clinical significance of EGFR amplification in patients with EGFR-mutated metastatic non-small cell lung cancer receiving first-line osimertinibAlessandro Di Federico, Federica Pecci, Mark Jeng, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 29, 2023
Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLCJoao V Alessi, Xinan Wang, Arielle Elkrief, et al.Nature Communications|July 24, 2025
Machine-learning driven strategies for adapting immunotherapy in metastatic NSCLCMaliazurina B Saad, Qasem Al-Tashi, Lingzhi Hong, et al.Pageof 11